Introduction
While efficacious in certain virus-mediated cancers, adoptive T-cell therapy generally fails to induce meaningful anti-cancer responses in patients with solid tumors. The cause for this lack of clinical efficacy is multi-factorial by nature and includes the intrinsic or acquired resistance of malignant cells to cytotoxic T-cell effector mechanisms such as granzyme/perforinmediated lysis (1) (2) (3) (4) (5) and Fas-mediated killing (6;7). To overcome or circumvent this potential pitfall of adoptive T-cell therapy, we propose to selectively expand the T-cell armamentarium with additional tumoricidal effector molecules, in particular with the Tumor Necrosis FactorRelated Apoptosis Inducing Ligand (TRAIL).
TRAIL is a type II transmembrane protein normally expressed on NK cells, where it is essential for NK-cell-mediated tumor immune surveillance (8;9) . In contrast, the expression of TRAIL on resting T-cells is typically very low (10;11). Nevertheless, a slight induction of TRAIL expression on T-cells, by ectopic expression of TRAIL or by ex vivo co-stimulation with anti-CD3 and IFN-Į, already potently increases their tumoricidal activity (11;12). Furthermore, T-cell expressed TRAIL is essential for graft versus tumor (GVT) activity during allogeneic hematopoietic cell transplantation (AHCT) (10). Importantly, T-cell expressed TRAIL does not contribute to deleterious graft versus host disease (GVHD) activity (10). Taken together, these findings suggest that T-cells should gain additional tumoricidal potential when equipped with TRAIL at the cell surface.
Previously, we and others have reported on an approach that may be particularly useful in this respect. In brief, recombinant soluble TRAIL (sTRAIL) was genetically linked to a tumor cell-selective antibody fragment (scFv). The resultant recombinant scFv:sTRAIL fusion protein has the following properties: by virtue of the antibody fragment, the scFv:TRAIL fusion protein selectively delivers TRAIL to the cell surface of tumor cells. Subsequently, cell surface bound scFv:TRAIL can activate TRAIL-receptor apoptotic signalling in tumor cells (reviewed in (13)).
Here, we utilized and adapted this approach to the selective delivery of high levels of TRAIL to the cell surface of T-cells, with the aim of expanding the cytotoxic armament of these Tcells with TRAIL (for schematic see Fig.1 ).
This approach was pre-clinically evaluated using two novel recombinant fusion proteins, supplemented with 10% fetal calf serum.
Isolation of primary patient-derived tumor cells, T-cells and activation of T-cells
Experiments were approved by the local Medical Ethical Committee and patients/healthy volunteers signed for informed consent. Tumor tissues and ascitic fluids were obtained during surgery procedures and if necessary minced, after which adherent cells were cultured.
Experiments were performed before passage number 5. Samples with a background apoptosis >30% were excluded from analysis. Normal fibroblast cultures originating from tumor tissue/ascitis were essentially established as described above for primary cancer cell cultures. Tumor infiltrating T-cells were isolated from the primary tumor cultures using Ammonium Chloride lysis. Peripheral blood lymphocytes (PBL) from blood of healthy donors were isolated using standard density gradient centrifugation (Lymphoprep, Axis-Shield PoC As., Oslo, Norway). Activated T cells were generated by culturing PBLs with anti-CD3 mAb (0.5μg/mL; 72h) and IL-2 (100ng/mL; 48h).
Analysis of fusion protein binding and TRAILR expression
Research. The presence of cell surface-bound TRAIL was assessed by incubating cells with PEconjugated anti-TRAIL mAb B-S23 (Diaclone SAS) for 60 min at 4°C followed by 3 washes. Cells were subsequently measured on an Accuri C6 flow cytometer. Cell surface display of TRAIL in time was determined by incubating cells with 50 pg/T-cell K12:TRAIL or anti-CD3:TRAIL for 60 minutes at 4°C followed by 3 washes in PBS. Cells were then incubated at 37°C for the time-points indicated and TRAIL expression was determined by flow cytometry using PE-labeled mAb B-S23. The amount of K12:TRAIL or anti-CD3:TRAIL bound to an individual T-cell was determined using TRAIL ELISA. Briefly, 1x10 Goat-anti-Mouse Ab for 60 min at 4°C. Cells were subsequently washed 3 more times with PBS and TRAILR expression was determined using an Accuri C6 flow cytometer.
Analysis of cell death
For cell death assays, cancer cells were labeled with red fluorescent membrane label DiI (Invitrogen) in serum free medium for 15 min. followed by three washes in serum containing medium and subsequent culture in a 48-well plate (3.0x10 4 cells/well). After 24 hours, cancer cells were treated for 16 hours with T-cells (activated or resting) at the indicated ratios in the presence or absence of K12:TRAIL (50 pg/T-cell), anti-CD3:TRAIL (50 pg/T-cell) or anti-MCSP:TRAIL (50 pg/T-cell) after which apoptosis was assessed in tumor cells by loss of mitochondrial membrane potential (¨ψ) as previously described (14) using an Accuri C6 flow cytometer. Where indicated, caspase inhibitors were used at a final concentration of 10 ȝM.
Actinomycin D was used at a final concentration of 2 ȝg/mL. Anti-TRAIL (2E5) and anti-FasL 
Results

Tumoricidal activity of T-cells is potently augmented by delivery of TRAIL to the T-cell surface
In order to selectively deliver TRAIL to the cell surface of T-cells, the CD3-targeted fusion protein anti-CD3:TRAIL and the CD7-targeted fusion protein K12:TRAIL were generated. In line with literature, ex vivo activated T-cells obtained from healthy volunteers did not detectably express TRAIL ( Fig.2A) . Incubation of these TRAIL-negative T-cells with anti-CD3:TRAIL or K12:TRAIL lead to the display of high levels of TRAIL on the T-cell surface ( To assess for possible effects of TRAIL-receptor expression on the sensitivity of tumor cells to the potentiating effect of K12:TRAIL and anti-CD3:TRAIL on T-cell activity, TRAILR expression levels were determined in a panel of cell lines (see Table 1 ). There was no correlation between TRAILR expression and sensitivity to K12:TRAIL-mediated T-cell cytotoxicity (Fig.S2A-D) . Interestingly, there was a weak negative correlation (r 2 =0.48) with TRAIL-R4 expression in terms of sensitivity to anti-CD3:TRAIL mediated T-cell cytotoxicity (Fig.S2D ), but no correlation with TRAILR1, R2 and R3 (Fig.S2A-C) .
Taken together, anti-CD3:TRAIL and K12:TRAIL both potently augment the tumoricidal activity of activated T-cells toward cancer cell lines and patient-derived malignant cells by ~500-fold.
Anti-CD3:TRAIL induces tumoricidal activity by activation of resting T-cells
Anti-CD3:TRAIL comprises a T-cell stimulating CD3-antibody fragment. By virtue of this antibody fragment, anti-CD3:TRAIL might also be able to activate intrinsic cytotoxic effector mechanisms of T-cells. In line with this hypothesis, resting T-cells that lacked activity in coculture experiments with OvCAR-3 gained potent cytotoxic activity in the presence of anti-CD3:TRAIL (Fig.3A , 100% apoptosis at E:T ratio 10:1). In contrast, resting T-cells remained ineffective in the presence of K12:TRAIL, with no cytotoxicity even at the highest E:T ratio tested (Fig.3A) . Furthermore, anti-CD3:TRAIL consistently reduced long term outgrowth by >50% in ascitic fluid from ovarian cancer patients that contains both primary malignant cells and autologous T-cells ( Fig.3B and S3A ). Neither an anti-CD3 stimulatory mAb nor an untargeted soluble rhTRAIL preparation alone inhibited cancer cell outgrowth (Fig.3B ).
In line with these activating properties, anti-CD3:TRAIL induced a rapid calcium-flux in T-cells co-cultured with OvCAR-3 cells (Fig.S3B ) which was followed in time by an increase in the number of T-cells positive for the activation marker CD69 (Fig.S3C ) and the release of proinflammatory T-cell cytokines (Fig. S3D) . Interestingly, preventing cellular contact between Tcells and tumor cells abolished T-cell activation induced by anti-CD3:TRAIL (Fig.S3E) , as did the addition of TRAIL neutralizing and TRAILR-blocking antibodies (Fig.S3C) . In contrast, caspase inhibition did not block activation of anti-CD3:TRAIL-armed T-cells (Fig.S3C ), but did block induction of apoptosis by rhTRAIL (Fig.S5A ). Further analysis using T-cells
Research. 13 mechanically manipulated using a micropipet (Fig.S4A for schematic representation) indicated that anti-CD3:TRAIL-mediated T-cell activation was likely due to shear stress upon simultaneous binding of anti-CD3:TRAIL to CD3 on T-cells and TRAILR2 on tumor cells (Fig.S4A-C) .
K12:TRAIL and anti-CD3:TRAIL enhance tumoricidal activity of resting T-cells via distinct mechanisms
Based on these activating properties, T-cell cytotoxicity induced by anti-CD3:TRAIL may at least partly be attributable to stimulation of intrinsic T-cell cytotoxicity. Indeed, the potentiating effect on T-cell activity by anti-CD3:TRAIL, but not by K12:TRAIL, was dose-dependently blocked by the granzyme/perforin release inhibitor Concanamycin A (CMA) (Fig.3C and S5B ).
In addition, A375M cells overexpressing a mutant form of the TRAILR adaptor protein FADD (FADD-DED) that inhibits TRAILR mediated caspase activation, remained sensitive to treatment with T-cells+anti-CD3:TRAIL, but not to T-cells+K12:TRAIL (Fig.3D) . Inhibition of other typical cytotoxic T-cell effectors, such as the tumoricidal proteins FasL and TNF-Į, failed to inhibit apoptotic activity of anti-CD3:TRAIL/K12:TRAIL towards OvCAR-3 cells (Fig.3E ).
Apoptotic activity of anti-CD3:TRAIL/K12:TRAIL-armed T-cells was abrogated by a pancaspase inhibitor (Fig. 3E) and by inhibition of caspase-8 or caspase-9 (Fig. 3E) . Of note, the potentiating effect of anti-CD3:TRAIL on tumoricidal T-cell activity closely resembled that of Tcells redirected with the bispecific antibody Bis-1 (anti-CD3:anti-EpCAM), which was also abrogated by CMA (Fig.S5C) . Therefore, the mode of action of anti-CD3:TRAIL appears to be largely dependent on granzyme/perforin-mediated lysis, whereas K12:TRAIL functions via activation of initiator caspase-8/-9 and effector caspases. Furthermore, the inhibitory effect of caspase-9 blockade suggests that mitochondrial amplification of the caspase-8 apoptotic signal is required for effective tumoricidal activity. 
resulting in a median survival of only 7 days (Fig.4B and 4C) . Importantly, growth of HCT116-luc in vivo was significantly suppressed by co-treatment with K12:TRAIL and activated T-cells, compared to treatment with either K12:TRAIL or T-cells alone. Indeed, median survival was increased 6-fold and one mouse survived for the duration of the experiment (70d) with minimal residual disease (Fig.4A, 4B; 42d vs. 7d) . Of note, co-treatment with K12:TRAIL and T-cells did not have obvious off-target toxicity in these mice, with no apparent weight loss (data not shown). In addition, fibroblasts (NHDF-juv), normal kidney cells (HK-2) and endothelial cells (HUVEC) were resistant to co-treatment with K12:TRAIL and T-cells (Fig.   S5D) . Similarly, co-treatment of mice with T-cells and anti-CD3:TRAIL resulted in a striking increase in median survival with 4 out of 5 mice remaining tumor free for the duration of the experiment ( Fig.4A and 4C ). Treatment with anti-CD3:TRAIL alone had no effect on animal survival (Fig.4C) . Of note, while no deleterious effects on animal well being were observed during the course of the experiment, the in vitro treatment of NHDF-juv, HK-2 and HUVEC with T-cells and anti-CD3:TRAIL did trigger an increase in the percentage of apoptosis (Fig.S5D) . To determine whether T-cells localized to the intraperitoneally growing tumor cells, fluorescently labeled T-cells were followed up to 5 days in an i.p. tumor model with HCT116.luc (Fig.4D) . Treatment with activated T-cells or activated T-cells+anti-CD3:TRAIL resulted in co-localization of bioluminescent (tumor) and fluorescent (T-cell) signal in tumor nodes in the abdominal cavity after 2 days, but not after 5 days (Fig.4D ). Upon treatment with activated T-cells+K12:TRAIL (Fig.4D) , the T-cells were found to co-localize with tumor signal until tumor cells were eliminated (Fig. 4D) . Taken (Fig.5A) . In contrast, pre-treatment of OvCAR-3 cells with Valproic Acid (VPA) strongly optimized the potentiating effect of K12:TRAIL and anti-CD3:TRAIL on tumoricidal T-cell activity, with ~30% and ~50% cell death in OvCAR-3 at E:T ratio of 1:50, respectively ( Fig. 5A-C) . Interestingly, VPA enhanced the anti-tumor effect of K12:TRAIL, but not anti-CD3:TRAIL, towards two patient-derived tumor samples (Fig.5D) . T-cell localization was subsequently monitored at the indicated time-points using fluorescence together with tumor localization using bioluminescence. See also Video S5 and S6. 
